BerGenBio reports Phase I/II data for BGB324

BerGenBio ASA (OSE:BGBIO) said daily 200 mg bemcentinib (BGB324) plus EGFR inhibitor Tarceva erlotinib met the initial efficacy endpoint in the first stage of the Phase II

Read the full 279 word article

User Sign In